The Danaher Beacon for Brain Injury Diagnostics seeks to identify mild Traumatic Brain Injury (TBI) earlier and more precisely. Scientists will evaluate new blood-based biomarkers using highly sensitive technology from Beckman Coulter Diagnostics. This approach could potentially be adapted for diagnosis of other neurological conditions. WASHINGTON, May 9, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and...Read more
Total fiscal 2024 revenue increased 12% to $5.5 billion Total fiscal 2024 U.S. GAAP earnings per diluted share of $3.81; adjusted earnings per diluted share increased to $8.83 Targeted restructuring plan announced DUBLIN, IRELAND , May 08, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2024 fourth quarter ended March 31, 2024. Total revenue for the...Read more
MARLBOROUGH, Mass., May 8, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced today the election of Dr. Cheryl Pegus to its board of directors, effective immediately. Dr. Pegus has more than 25 years of clinical and business leadership experience, most recently serving as a partner at Morgan Health focused on improving the quality, affordability and equity of health care. Prior to that, Dr. Pegus was executive vice...Read more
Acquisition advances Labcorp's specialty testing strategy in key areas such as oncology and rare diseases Key milestone reached in Invitae's Chapter 11 process BURLINGTON, N.C. and SAN FRANCISCO, May 7, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and Invitae (OTC:NVTAQ), a leading medical genetics company, announced today that the United States Bankruptcy...Read more
WOBURN, Mass., May 3, 2024 /PRNewswire/ -- Curiox Biosystems Co. Ltd (Curiox), a leader in the innovation of life science research technologies, and Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, announce a strategic partnership to provide researchers with a one-stop solution for hands-free washed sample preparation for flow cytometry. The agreement combines the Laminar...Read more
Core Illumina revenue of $1.06 billion for Q1 2024, down 2% from Q1 2023 (down 2% on a constant currency basis) Core Illumina GAAP operating margin of 11.0% and non-GAAP operating margin of 20.6% for Q1 2024 Reiterating fiscal year 2024 Core Illumina revenue guidance that is approximately flat compared to 2023 and a Core Illumina non-GAAP operating margin for fiscal year 2024 of approximately 20% Consolidated revenue of $1.08 billion...Read more
First-quarter sales from continuing operations of $3.59 billion increased 2% on a reported basis and 3% on a constant currency basis, exceeding the company’s previously issued guidance1 First-quarter U.S. GAAP2 diluted earnings per share (EPS) from continuing operations were $0.07 and adjusted diluted EPS from continuing operations were $0.65, exceeding the company’s previously issued guidance Baxter now expects full-year 2024 sales...Read more
Revenue of $3,737 million GAAP Net Income of $288 million, Adjusted EBITDA of $862 million GAAP Diluted Earnings per Share of $1.56, Adjusted Diluted Earnings per Share of $2.54 R&D Solutions quarterly bookings of $2.6 billion, representing a book-to-bill ratio of 1.23x R&D Solutions contracted backlog of $30.1 billion, up 7.9 percent year-over-year RESEARCH TRIANGLE PARK, N.C. / May 02, 2024 / Business Wire / IQVIA...Read more
Revenue increased 9% to $54.9 billion GAAP1 operating earnings were $367 million; GAAP diluted EPS was $1.05 Non-GAAP operating earnings increased 10% to $666 million; non-GAAP diluted EPS increased 20% to $2.08 Fiscal year 2024 non-GAAP EPS guidance2 raised and narrowed to $7.30 to $7.40, from $7.20 to $7.35 Company provides preliminary fiscal year 2025 non-GAAP EPS guidance of at least $7.50 DUBLIN, Ohio, May 2, 2024 ...Read more
Margin Execution Drives Better Performance in Quarter and Higher Guidance for Fiscal 2024 Q2 revenue of $5.0 billion increased 4.6% as reported, 4.7% currency-neutral and 5.7% organic Q2 GAAP and adjusted diluted EPS of $1.85 and $3.17 grew 20.9% and 10.8%, respectively Year-to-date Cash from Continuing Operations of $1.4 billion and Free Cash Flow of $1.1 billion increased $785 million and over $900 million, respectively Company...Read more
SANTA CLARA, Calif. / May 01, 2024 / Business Wire / Agilent Technologies Inc. (NYSE:A) today announced that Padraig McDonnell has assumed the role of Agilent CEO, effective immediately. His appointment is part of the company’s CEO transition plan announced Feb. 21. McDonnell is the fourth CEO in Agilent’s history and succeeds Mike McMullen, who will serve as an adviser until he retires Oct. 31. “It’s an incredible honor to serve as CEO of...Read more
Portage, Michigan, April 30, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2024: First Quarter Results Reported net sales increased 9.7% to $5.2 billion Organic net sales increased 10.0% Reported operating income margin of 18.5% Adjusted operating income margin(1) increased 80 bps to 21.9% Reported EPS increased 33.1% to $2.05 Adjusted EPS(1) increased 16.8% to...Read more
More than 20 million people in the U.S. are living with peripheral artery disease (PAD) yet there have been limited treatment options The first-of-its-kind Esprit™ BTK Everolimus Eluting Resorbable Scaffold dissolves over time after it has opened blocked arteries below the knee (BTK) The Esprit BTK System is a dissolving stent that offers the possibility of better outcomes for people with the most severe form of PAD ABBOTT PARK,...Read more
Assay expands company's leadership in precision medicine and cell and gene therapy BURLINGTON, N.C., April 29, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the U.S. Food and Drug Administration (FDA) has approved its nAbCyte™ Anti-AAVRh74var HB-FE Assay, a companion diagnostic (CDx) to determine patient eligibility for treatment with...Read more
SANTA CLARA, Calif. / Apr 29, 2024 / Business Wire / Agilent Technologies, Inc. (NYSE: A) today announced Simon May has been named president of the company’s Diagnostics and Genomics Group (DGG). May, previously executive vice president and president of the Life Science Group at Bio-Rad Laboratories, will join Agilent on May 6. “We are excited to welcome Simon May to the Agilent team,” said Padraig McDonnell, COO and CEO-elect. “Simon’s...Read more
Closed-loop sensing capability instantly and automatically adjusts therapy while treating chronic pain DUBLIN, April 26, 2024 /CNW/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the U.S. Food and Drug Administration (FDA) has approved the Inceptiv™ closed-loop rechargeable spinal cord stimulator (SCS) for the treatment of chronic pain. Inceptiv is the first Medtronic SCS device to...Read more
IRVINE, Calif. / Apr 25, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2024. Highlights and Outlook Q1 sales grew 10% on a reported and constant currency1 basis to $1.6 billion Q1 TAVR sales grew 6%; constant currency sales grew 8% adjusted for billing days Q1 TMTT sales grew 75% Q1 EPS of $0.58; adjusted1 EPS of $0.66 Raising 2024 sales guidance to the high...Read more
Year-over-year revenue grows 7%, operating profit up 25%, non-GAAP operating profit up 23% Operating cash flows of $402 million Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2024. Third Quarter 2024...Read more
SAN DIEGO / Apr 25, 2024 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2024. First Quarter 2024 Financial Highlights: Revenue grew 24% year-over-year to $921.0 million on a reported basis and 25% year-over-year on an organic1 basis. U.S. revenue and international revenue both grew 24% on a reported basis and international revenue grew 26% on an organic1...Read more
Updates Full-Year Guidance Results from Continuing Operations for first quarter 2024 versus last year: Revenue: $3.18 billion versus $3.04 billion or up 4.6% | Base Business grew 6.7% Diluted EPS: $2.69 versus $2.34 Adjusted EPS: $3.68 versus $3.46 Full-Year 2024 Guidance: Raised midpoint and narrowed range of adjusted EPS to $14.45 to $15.35; Free Cash Flow remains $1.00 billion to $1.15 billion Year to date...Read more
Conference Call Scheduled for 9 a.m. EDT Today EXTON, Pa., April 25, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the first-quarter 2024 and updated full-year 2024 financial guidance. First-Quarter 2024 Summary (comparisons to prior-year period) Net sales of $695.4 million declined 3.0%; organic net sales also declined by 3.0%. Reported-diluted EPS of $1.55...Read more
Highlights Net business wins in the quarter of $2,654 million; a net book to bill of 1.27, an increase of 9.9% on quarter one 2023. Closing backlog of $23.4 billion, an increase of 2.5% on quarter four 2023 and 10.1% on quarter one 2023. Quarter one revenue of $2,090.4 million representing an increase of 5.7% on prior year revenue and 5.4% on a constant currency basis. Quarter one adjusted EBITDA of $444.0 million or 21.2%...Read more
MARLBOROUGH, Mass., April 24, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.856 billion during the first quarter of 2024, growing 13.8 percent on a reported basis, 15.0 percent on an operational1 basis and 13.1 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $495 million or $0.33 per...Read more
WALTHAM, Mass. / Apr 24, 2024 / Business Wire / Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 30, 2024. First Quarter 2024 Highlights First quarter revenue was $10.34 billion. First quarter GAAP diluted earnings per share (EPS) increased 4% to $3.46. First quarter adjusted EPS increased 2% to $5.11. Advanced our proven growth...Read more
WASHINGTON, April 23, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended March 29, 2024. All results in this release reflect only continuing operations unless otherwise noted. Key First Quarter 2024 Results Net earnings were $1.1 billion, or $1.45 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.92. Revenues decreased...Read more
SUNNYVALE, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended March 31, 2024. Q1 Highlights Worldwide da Vinci procedures grew approximately 16% compared with the first quarter of 2023. The Company placed 313 da Vinci surgical systems,...Read more
Sales of $10.0 billion driven by strong underlying base business performance Reported sales increased 2.2 percent, which includes the impact from the anticipated decline in COVID-19 testing-related sales versus prior year Organic sales growth for underlying base business of 10.8 percent, which represents the fifth consecutive quarter of double-digit growth1 ABBOTT PARK, Ill., April 17, 2024 /PRNewswire/ -- Abbott (NYSE: ABT)...Read more
SANTA CLARA, Calif. / Apr 15, 2024 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced that its GenetiSure Dx Postnatal Assay has received European IVDR Class C Certification. This certification demonstrates that the assay meets the higher standards established by IVDR. It ensures the continued availability of this trusted qualitative assay to clinical geneticists and other healthcare professionals throughout the EU. In...Read more
Innovative GFAP blood biomarker test expands Labcorp's portfolio of tests for diseases including Alzheimer's disease, multiple sclerosis, glioblastoma and brain injuries BURLINGTON, N.C., April 15, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the availability of the nation's first test for glial fibrillary acidic protein (GFAP), a critical blood-based...Read more
Five new launches reinforce Baxter’s focus on differentiated products and enhance the company’s Pharmaceuticals portfolio in critical therapeutic areas Products feature ready-to-use formulations to help support patient safety and offer added convenience for healthcare professionals DEERFIELD, Ill. / Apr 11, 2024 / Business Wire / Baxter International Inc. (NYSE:BAX), a global leader in injectables, anesthesia and drug compounding,...Read more
The first at-home mpox testing kit provides patients with convenience and privacy to test for mpox, supports physicians in detection and treatment BURLINGTON, N.C., April 10, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its Mpox PCR Test Home...Read more
Joydeep Goswami to serve as advisor through June 30 Illumina reaffirms Q1 2024 and full-year 2024 financial guidance SAN DIEGO, April 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that Joydeep Goswami has decided to leave Illumina. He will stay on in an advisory role through June 30 to support two new executive management team...Read more
RESEARCH TRIANGLE PARK, N.C. & SAN FRANCISCO, CA / Apr 08, 2024 / Business Wire / IQVIA (NYSE:IQV), a leading global provider of data, analytics, technology and services to the life sciences industry, and Salesforce (NYSE:CRM), the #1 AI CRM, today announced an expanded global strategic partnership to accelerate the development of Salesforce’s Life Sciences Cloud, a next-generation customer engagement platform for the global life...Read more
EHRA late-breaking data: Results highlight efficacy, safety, and durability of the novel PFA catheter that is fully integrated with Affera™ Mapping and Ablation System DUBLIN and BERLIN, April 8, 2024 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive clinical trial safety and efficacy results for Sphere-360™, an investigational single-shot mapping and ablation...Read more
MARLBOROUGH, Mass., April 8, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated the NAVIGATE-PF study of the FARAVIEW™ Software Module* when it is used to visualize and track the FARAWAVE™ Nav Pulsed Field Ablation (PFA) Catheter* for the treatment of patients with paroxysmal and persistent atrial fibrillation (AF). The FARAVIEW technology and the FARAWAVE Nav catheter expand the capabilities of the...Read more
New data from largest head-to-head randomized control TAVR trial demonstrates non-inferior clinical outcomes and superior valve performance for Evolut TAVR compared to Sapien™ at one year DUBLIN and ATLANTA, April 7, 2024 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced new data from the largest head-to-head comparative trial of transfemoral transcatheter aortic valve replacement...Read more
Despite prevalence of chronic conditions associated with aortic stenosis in women over 65, the majority have never been referred to a cardiologist; Racial disparities may present further opportunities for awareness amongst women at risk for cardiovascular disease DUBLIN, April 7, 2024 /CNW/ -- Medtronic plc, a global leader in healthcare technology, today unveiled topline findings of its comprehensive survey on women's...Read more
Labcorp Plasma Detect is the first clinically validated, whole-genome sequencing MRD solution for early-stage colon cancer BURLINGTON, N.C., April 5, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Labcorp® Plasma Detect™, the first clinically validated, tumor-informed, whole-genome sequencing circulating tumor DNA (ctDNA) molecular...Read more
TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery More than 1.6 million people in the U.S. are affected by tricuspid regurgitation,1 which can severely impact quality of life Data from the TRILUMINATE™ Pivotal trial demonstrated that patients who received TriClip experienced a marked improvement in the severity of their symptoms...Read more
The Consumer Health Logistics Center will be located in Central Ohio and serve as a centralized hub for distribution of consumer health products COLUMBUS, Ohio, April 2, 2024 /PRNewswire/ -- Today, Cardinal Health (NYSE: CAH) announced that construction has begun for a new 350,000 square-foot logistics center in Columbus, Ohio, that will serve as a centralized replenishment center for the distribution of over-the-counter...Read more
The test, run on Abbott's portable i-STAT® Alinity® instrument, uses whole blood to help evaluate patients with a suspected mild traumatic brain injury (mTBI), or concussion The test produces lab-quality results in 15 minutes Clinicians are now able to get a result at the patient's bedside, making the test accessible at urgent care clinics and other healthcare settings outside the hospital emergency room The test can be used to help...Read more
Longstanding partnership deepens with new financing, beta access to clinical manufacturing instruments, and AACR data presentations SAN FRANCISCO / Apr 01, 2024 / Business Wire / Xcell Biosciences Inc. (Xcellbio), an instrumentation company focused on cell and gene therapy applications, today announced it has added new elements to its research collaboration agreement with Labcorp, a global leader of innovative and comprehensive...Read more
Novum IQ Infusion Platform now offers large volume and syringe infusion smart pumps on an integrated system with shared innovative digital health solutions to help enhance patient safety and efficiency for clinicians Common user interface and connectivity across both pump modalities are designed to help reduce workflow burden and allow more time focused on patient care DEERFIELD, Ill. / Apr 01, 2024 / Business Wire / Baxter...Read more
The Evolut™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access DUBLIN, March 27, 2024 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has approved the Evolut™ FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe...Read more
Addition of pTau217 test further expands the company's leadership in testing options for Alzheimer's disease to improve patient care BURLINGTON, N.C., March 20, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch and immediate availability of its test to identify the presence or absence of phosphorylated tau 217 (pTau217), a pivotal blood...Read more
Abbott's Eterna™ SCS system to treat chronic pain was used for the first time in Canada at Hôpital de l'Enfant-Jésus hospital in Quebec City.The device is the smallest implantable rechargeable spinal cord stimulator (SCS)*3 and provides the ability to deliver therapy while only requiring wireless recharging five times per year,1,2 meaning less frequent charging for the chronic pain patients being...Read more
Outcomes point to value of biomarker testing in addressing testing gaps in clinical practice BURLINGTON, N.C., March 16, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today presented the results from two studies at the 2024 SGO Annual Meeting on Women's Cancer. The studies demonstrate the value of biomarker testing in closing testing gaps and guiding...Read more
SUNNYVALE, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced today that the U.S. Food and Drug Administration (FDA) provided 510(k) clearance for da Vinci 5, the company’s next-generation multiport robotic system. “We are pleased to receive FDA clearance for our fifth-generation robotic system, da Vinci 5,” said...Read more
Results Show Clinical Workflow, Operational Efficiency and Financial Improvements When Using Automated Dispensing Cabinets FRANKLIN LAKES, N.J., March 13, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced new data from a research study evaluating the impact of deploying automated dispensing cabinets in long-term care facilities and an...Read more
WASHINGTON / Mar 11, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) announced today at Cardiovascular Research Technologies (CRT) 2024 the compelling results from two large, real-world studies based on TVT Registry data that demonstrated continued excellent outcomes for patients treated with the Edwards SAPIEN valve platform. A study of Edwards’ latest TAVR technology, the SAPIEN 3 Ultra RESILIA valve, found lower rates of...Read more
New data presented at ATTD demonstrates the system's ability to help individuals with type 1 diabetes exceed international targets on outcome measures DUBLIN and FLORENCE, Italy, March 9, 2024 /PRNewswire/ -- Medtronic plc. (NYSE: MDT), a global leader in healthcare technology, today shared a robust set of new clinical and real-world evidence on the MiniMed™ 780G system from around the world including the largest set of data...Read more
New offering to support individuals and physicians with accessible and convenient testing options to guide weight loss management decisions and treatments BURLINGTON, N.C., March 7, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the introduction of its Weight Loss Management portfolio. The new offering features educational resources and convenient...Read more
Enhances sleep apnea therapy by combining the ease and comfort of an ultra-compact, under-the-nose full-face design with the effectiveness of a traditional over-the-nose full-face mask. Featuring the AdaptiSeal™ cushion made of 100% soft silicone to adapt to various facial contours, allowing for a secure and comfortable seal throughout the night. 96% of patients using the AirFit F40 said they have the freedom to sleep in their...Read more
Data analyses show that people with Type 2 diabetes using GLP-1 medicines saw a significant improvement in their HbA1C after adding FreeStyle Libre technology to their regimen Better HbA1c results were achieved irrespective of GLP-1 duration, GLP-1 type, or insulin therapy type FreeStyle Libre systems help people adhere to diabetes treatment plans and support positive behavior changes by providing real-time data that shows how food,...Read more
Vivity is the most implanted extended depth of focus (EDOF) intraocular lens (IOL) globally1 Milestone underscores the impact of Vivity’s first-of-its-kind, patented wavefront-shaping technology, which simplifies presbyopia correction for surgeons and patients2,3 Vivity demonstrates excellent outcomes, with real-world Vivity Registry data from more than 900 cataract patients, including patients with certain mild comorbidities as well as...Read more
Stelo will be the first glucose biosensor in the US cleared for use without a prescription Indicated for use for people 18 years and older who are not using insulin therapy A small, wearable sensor worn on the back of the upper arm, Stelo will provide glucose insights directly to a user’s smartphone† Created by the makers of Dexcom G7, the most accurate,1 easy-to-use2 and clinically-proven CGM brand,3-7 Stelo will empower even more...Read more
First Patient Enrollment in AGILITY Study Begins Investigations of Safety and Effectiveness of BD Vascular Covered Stent for Treatment of PAD FRANKLIN LAKES, N.J., March 4, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the enrollment of the first patient in the investigational device exemption (IDE) study, "AGILITY," which will assess the safety...Read more
First coronary drug-coated balloon in U.S. provides safe, effective alternative to treat coronary in-stent restenosis and reduce risk of reoccurrence MARLBOROUGH, Mass., March 1, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the AGENT™ Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in...Read more
DUBLIN, Ohio, Feb. 28, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors has elected Robert "Bob" Azelby as an independent director, effective March 1. Mr. Azelby joins the board with over 30 years of experience, including as a Chief Executive Officer and board member for large, matrixed organizations in the biopharmaceutical, oncology and other specialty industries. Mr. Azelby...Read more
Q4 2023 sales of $2.3 billion, up 8%, or 10% constant currency(1) (cc) Q4 2023 diluted EPS of $0.86, compared to a loss in the prior year(3); core diluted EPS(2) of $0.70 up 67%, or 78% cc FY 2023 sales of $9.4 billion, up 8%, or 10% cc FY 2023 diluted EPS of $1.96, up 188%; core diluted EPS of $2.74, up 22%, or 33% cc FY 2024 outlook: 6% to 8% cc sales growth, 13% to 16% cc core diluted EPS growth Ad Hoc Announcement Pursuant to...Read more
Revenue and earnings exceed Q1 guidance Full-year outlook maintained Highlights Revenue of $1.66 billion, down 5.6% reported and 6.4% core(1) from the first quarter of 2023. GAAP net income of $348 million; earnings per share (EPS) of $1.18, down 1% from the first quarter of 2023. Non-GAAP(2) net income of $380 million; EPS of $1.29, down 6% from the first quarter of 2023. Full-year revenue outlook maintained at $6.710 billion...Read more
DUBLIN / Feb 26, 2024 / Business Wire / ICON plc, (NASDAQ: ICLR) a world-leading clinical research organization powered by healthcare intelligence, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the TD Cowen 44th Annual Healthcare Conference on Tuesday, March 5, 2024 at 11:10 am ET and Dr. Steve Cutler, CEO of ICON plc, will present at the Barclays 26th Annual Global Healthcare Conference on Tuesday, March 12,...Read more
Highlights Net business wins in the quarter of $2,531 million; a net book to bill of 1.22. Full year net business wins of $9,946 million; a net book to bill of 1.22. Closing backlog of $22.8 billion, an increase of 2.4% on quarter three 2023 and an increase of 10.0% on quarter four 2022. Quarter four revenue of $2,066.2 million representing an increase of 5.3% on prior year revenue. Full year revenue of $8,120.2 million representing a...Read more
First-Ever Program in the Country to Offer At-Home Self-Collection of Samples for HPV Testing SINGAPORE, Feb. 21, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a strategic partnership with Camtech Health, a digital health company focused on at-home health testing, to advance cervical cancer screening by offering the first-ever option for women in...Read more
Delivers on commitments with strong growth in Core Spine, Cardiac Surgery, Structural Heart, Cardiac Pacing, and across many international markets; Diabetes increases double digits as U.S. business returns to growth; Raises full year guidance DUBLIN, Feb. 20, 2024 /CNW/ -- Medtronic plc (NYSE:MDT) today announced financial results for its third quarter (Q3) of fiscal year 2024 (FY24), which ended January 26, 2024. Key...Read more
Company Provides 2024 Guidance Results from Continuing Operations for the fourth quarter and full year versus last year: Revenue: Q4 of $3.03 billion vs $2.93 billion; Full year of $12.16 billion vs $11.86 billion Diluted EPS: Q4 of $(1.95) vs $0.42 ; Full year of $4.33 vs $10.94 Adjusted EPS: Q4 of $3.30 vs $3.05 ; Full year of $13.56 vs $16.66 Free Cash Flow: Q4 of $414.2 million vs $508.1 million; Full year of $748.7 million...Read more
Conference Call Scheduled for 9 a.m. EST Today EXTON, Pa., Feb. 15, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the fourth-quarter and full-year 2023 and introduced full-year 2024 financial guidance. Fourth-Quarter and Full-Year 2023 Summary (comparisons to prior-year period) Fourth-quarter 2023 net sales of $732.0 million grew 3.3%; organic net sales growth...Read more
Revenue of $3,868 million for the fourth quarter, $14,984 million for the full year GAAP Net Income of $469 million for the fourth quarter, $1,358 million for the full year Adjusted EBITDA of $966 million for the fourth quarter, $3,569 million for the full year GAAP Diluted Earnings per Share of $2.54 for the fourth quarter, $7.29 for the full year Adjusted Diluted Earnings per Share of $2.84 for the fourth quarter, $10.20 for the...Read more
Panel of independent experts reviewed data from the TRILUMINATE™ pivotal trial demonstrating safety, effectiveness and quality-of-life benefits of the TriClip system An investigational device in the U.S., TriClip is approved in more than 50 countries and has treated more than 10,000 people with tricuspid regurgitation worldwide ABBOTT PARK, Ill., Feb. 13, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that...Read more
Enhances availability of device therapy options, particularly for those who struggle with single pressure PAP therapy Part of Air11 Solutions, key features include Care Check-in, Personal Therapy Assistant, among others to provide support to patients and insights to clinicians and providers when used with AirView and myAir app SAN DIEGO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) launched today its AirCurve 11...Read more
Revenue of $1.12 billion for Q4 2023, up 4% from Q4 2022 (up 4% on a constant currency basis) Revenue of $4.50 billion for fiscal year 2023, down 2% from fiscal year 2022 (flat on a constant currency basis) Shipped 79 NovaSeq X instruments in Q4 2023 and 352 instruments for fiscal year 2023 GAAP diluted loss per share of $(1.11) for Q4 2023, compared to GAAP diluted loss per share of $(0.89) for Q4 2022 Non-GAAP diluted earnings per...Read more
SAN DIEGO / Feb 08, 2024 / Business Wire / DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights: Revenue grew 27% versus the same quarter of the prior year to $1.03 billion on a reported basis and 26% on an organic1 basis. U.S. revenue growth of 27% and international revenue growth of 27% on a reported basis....Read more
Fourth-quarter sales from continuing operations of $3.89 billion increased 4% on a reported basis and 3% on a constant currency basis1 Fourth-quarter U.S. GAAP diluted earnings per share (EPS) from continuing operations of $0.14 and adjusted diluted EPS from continuing operations of $0.88 Full-year sales from continuing operations of $14.81 billion increased 2% on a reported basis and 3% on a constant currency basis Full-year U.S. GAAP...Read more
Third quarter revenue increases 15% as reported; 10% constant currency organic As reported diluted earnings per share increased to $1.42; adjusted earnings per share increased to $2.22 Fiscal 2024 outlook updated DUBLIN, IRELAND, Feb. 07, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2024 third quarter ended December 31, 2023. Revenue as reported for the...Read more
IRVINE, Calif. / Feb 06, 2024 / Business Wire / Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2023. Highlights and Outlook Q4 sales grew 14 percent to $1.53 billion; constant currency1 sales grew 13 percent Q4 TAVR sales grew 13 percent; constant currency sales grew 12 percent Q4 EPS of $0.61; adjusted1 EPS of $0.64 2023 sales of $6.0 billion grew 12 percent; EPS of $2.30;...Read more
Danaher Beacon for Preclinical Drug Safety seeks to address major cause of failure in clinical trials Program will leverage automated liver organoid technology for drug toxicity screening Aims to expand genetic diversity of screening, accelerate therapy development, and help ensure patient safety WASHINGTON, Feb. 5, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator, today launched...Read more
IRVINE, Calif. / Feb 02, 2024 / Business Wire / Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR). The EVOQUE system is indicated for the improvement of health status in patients with symptomatic severe TR despite optimal medical...Read more
The first and only monthly Water Gradient multifocal contact lens that feels like nothing – even at day 301 Provides excellent visual acuity at all distances, near through far, with Alcon’s proven Precision Profile design that fits in two easy steps, delivering 96% fit success2-4 New TOTAL30 Multifocal contact lenses will help address the vision and comfort needs of the global multifocal market, which is growing faster than the overall...Read more
Revenue increased 12% to $57.4 billion GAAP1 operating earnings were $482 million; GAAP diluted EPS was $1.43 Non-GAAP operating earnings increased 20% to $562 million; non-GAAP diluted EPS increased 38% to $1.82 Fiscal 2024 non-GAAP EPS guidance raised to $7.20 to $7.35, from $6.75 to $7.002,3 Fiscal 2024 non-GAAP adjusted free cash flow guidance raised to ~$2.5 billion, from ~$2.0 billion Cardinal Health to acquire Specialty...Read more
Margin Execution Drives Better Performance in Quarter and Higher Guidance for Fiscal 2024 Q1 revenue of $4.7 billion increased 2.6% as reported, 1.6% currency-neutral and 2.4% organic Q1 GAAP and adjusted diluted EPS from continuing operations of $0.96 and $2.68, respectively Company raises full-year adjusted EPS guidance and midpoint of organic revenue growth guidance FRANKLIN LAKES, N.J., Feb. 1, 2024 /PRNewswire/ -- BD...Read more
The PROTALITY™ brand provides nutritional support for adults pursuing weight loss in the form of a high-protein nutrition shake featuring a blend of fast- and slow-digesting protein designed to feed muscles for up to seven hours As people eat less and lose weight, a portion of what's lost may be from muscle, which is vital to overall health and physical functioning More than 7 in 10 adults are overweight or have obesity in the U.S....Read more
Stryker’s Footprint and Infinity Total Ankle System will be featured at the American College of Foot and Ankle Surgeons Annual Meeting PORTAGE, Mich. / Jan 31, 2024 / Business Wire / Stryker (NYSE: SYK), a global leader in medical technologies, today announced the launch of Prophecy Footprint, an expansion of the Prophecy Surgical Planning system, offering comprehensive surgical planning across the entire foot. The system will be...Read more
B•R•A•H•M•S™ sFlt-1/PlGF KRYPTOR™ Test System is available through physicians and is the first FDA-cleared biomarker test to aid in the risk assessment of progression to preeclampsia with severe features, a leading cause of maternal and fetal mortality in the U.S.1 BURLINGTON, N.C., Jan. 31, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the launch...Read more
Transaction creates increased clinical and economic value for 11,500 specialty providers, including more than 7,000 physicians across 1,200 independent physician practices Transaction creates platform for Cardinal Health expansion across specialty therapeutic areas Transaction enhances capabilities of Cardinal Health Specialty and supports ongoing build of Navista™ Network DUBLIN, Ohio, Jan. 31, 2024 /PRNewswire/ -- Cardinal...Read more
MARLBOROUGH, Mass., Jan. 31, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.725 billion during the fourth quarter of 2023, growing 14.9 percent on a reported basis, 14.5 percent on an operational1 basis and 13.6 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $504 million or...Read more
Strong clinical evidence base, largest volume of real-world use reinforce safety, efficacy and efficiency advantages of the system MARLBOROUGH, Mass., Jan. 31, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval for the FARAPULSE™ Pulsed Field Ablation (PFA) System. The FARAPULSE PFA System is indicated for the isolation of pulmonary veins in...Read more
WALTHAM, Mass. / Jan 31, 2024 / Business Wire / Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter and Full Year 2023 Highlights Fourth quarter revenue was $10.89 billion, 5% lower versus the same quarter last year. Core organic revenue growth declined 4%. Fourth quarter GAAP diluted EPS was...Read more
Portage, Michigan, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2023: Fourth Quarter Results Reported net sales increased 11.8% to $5.8 billion Organic net sales increased 11.4% Reported operating income margin of 21.6% Adjusted operating income margin(1) increased 60 bps to 27.2% Reported EPS increased 102.7% to $2.98 Adjusted EPS(1) increased 15.3% to...Read more
SANTA CLARA, Calif. / Jan 30, 2024 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced an agreement with Incyte that will bring together Agilent’s expertise and proven track record in the development of companion diagnostics (CDx) to support the development and commercialization of Incyte’s hematology and oncology portfolio. The value of the companion diagnostics market is predicted to expand to nearly US $14B by 2030,1...Read more
AI-Based Algorithm Aims to Enable Cytotechnologists and Pathologists to Efficiently Identify Evidence of Cervical Cancer and Precancerous Lesions FRANKLIN LAKES, N.J. and OREM, Utah, Jan. 30, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Techcyte, a world leader in artificial intelligence (AI)-based digital diagnostics, today announced a strategic collaboration...Read more
| Company | Change | Last Trade |
|---|---|---|
| Mettler-Toledo | 23.75 1.59 | $1,519.89 |
| Intuitive Surgical | 15.20 3.96 | $399.39 |
| Stryker | 7.69 2.37 | $331.99 |
| ICON | 6.23 1.97 | $321.80 |
| ResMed | 4.78 2.21 | $220.63 |
| Thermo Fisher Scientific | 4.22 0.71 | $599.02 |
| Danaher | 4.20 1.62 | $263.46 |
| DexCom | 3.74 2.97 | $129.71 |
| Edwards Lifesciences | 3.70 4.28 | $90.16 |
| Agilent Technologies | 2.80 1.85 | $154.08 |
| IQVIA | 2.55 1.10 | $233.69 |
| Becton Dickinson | 2.29 0.97 | $237.29 |
| Labcorp | 2.01 0.95 | $213.21 |
| Zimmer Biomet | 1.01 0.84 | $120.98 |
| Boston Scientific | 0.96 1.31 | $74.45 |
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
